האגודה למלחמה בסרטן - במה - גיליון מס' 24 - אוגוסט 2021

רשימת ספרות

1. Mertens F, Antonescu CR, Mitelman F. Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes. Genes Chromosomes Cancer. 2016 Apr;55(4):291–310. Epub 2015 Dec 18. 2. Arbiser ZK, Folpe AL, Weiss SW. Consultative (expert) second opinions in soft tissue pathology: analysis of problem-prone diagnostic situations. Am J Clin Pathol. 2001 Oct;116(4): 473–6. 3. Randall RL, Bruckner JD, Papenhausen MD, et al. Errors in diagnosis and margin determination of soft-tissue sarcomas initially treated at non-tertiary centers. Orthopedics. 2004 Feb;27(2):209-12. 4. Thway K, Fisher C. Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre. Sarcoma. 2009; 2009:741975. Epub 2009 May 27. 5. Avenarius MR, Miller CR, Arnold MA, et al. Genetic characterization of pediatric sarcomas by targeted RNA sequencing. J Mol Diagn. 2020 Oct;22(10):1238-45. Epub 2020 Aug 1. 6. Racanelli D, Brenca M, Baldazzi D, et al. Next- generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC Sarcoma Working Group. Front Oncol. 2020 Apr 15;10:489. 7. Chang KTE, Goytain A, Tucker T, et al. Development and evaluation of a pan-sarcoma fusion gene detection assay using the NanoString nCounter Platform. J Mol Diagn. 2018 Jan;20(1):63-77. Epub 2017 Nov 20.

8. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype- tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open- label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 Jun;18(6):812-22. Epub 2017 May 9. 9. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation- related sarcomas. Eur J Cancer. 2014 Apr;50(6):1137- 47. Epub 2014 Feb 7. 10. Assi T, Kattan J, Rassy EE, et al. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. Cancer Treat Rev. 2019 Jan;72:37-44. Epub 2018 Nov 15. 11. Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: management based on the European experience. J Clin Oncol. 2010 Jan;28(2):318-23. Epub 2009 Nov 16. 12. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 Apr;21(4):531–40. Epub 2020 Feb 24. 13. Orbach D, Sparber-Sauer M, Laetsch TW, et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies. E J Cancer. 2020 Sep;137:183-92. Epub 2020 Aug 9.

14. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013 March 28;153(1):71–85. 15. Jerby-Arnon L, Neftel C, Shore ME, et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021 Feb;27(2)289-300. Epub 2021 Jan 25. 16. Robbins PF, Kassim SH, Tran TLN, et al. A pilot trial using lymphocytes genetically engineered with an NY- ESO-1-reactive T cell receptor: long term follow up and correlates with response. Clin Cancer Res. 2015 Mar 1;21(5):1019–27. Epub 2014 Dec 23. 17. D'Angelo P, Melchiori L, Merchant MS, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259 T cells in synovial sarcoma. Cancer Discov. 2018 Aug;8(8):944–57. Epub 2018 Jun 11. 18. Somaiah N, Chawla ST, Block MS, et al. A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1. Oncoimmunology. 2020 Nov;19(1):1847846. 19. Marcus L, Lemery SJ, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019 Jul 1;25(13):3753-58. Epub 2019 Feb 20.

23